pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Fierce Biotech·10h ago·1 min read
save

Rare inherited EGFR mutation raises lung cancer risk 62-fold in never-smokers, 25-fold in smokers

Sep 17, 2026·read at Fierce Biotech ↗Neutral

Researchers examined genotyping data from 23andMe covering 3.37 million individuals and found the T790M germline mutation in about one out of every 15,850 people.

The study reported that carriers of this rare EGFR variant face a 62 times higher chance of developing lung cancer if they have never smoked, and a 25 times higher chance if they do smoke, compared with the general population where smoking alone raises risk about fourfold.

The mutation showed a strong link only to lung cancer among the 17 cancers and non‑pulmonary conditions screened, and its origins were traced to southern Appalachian populations in the United States.

Experts noted that current lung‑cancer screening programs rely mainly on tobacco exposure and suggested that genetic testing for this variant could help identify additional high‑risk individuals for earlier detection and treatment.

source

This writeup was produced by pharmadog from original reporting by Fierce Biotech.

Original headline: “Rare EGFR mutation increases lung cancer risk 62 times in never smokers”

read at Fierce Biotech ↗
498 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Ultragenyx Pharmaceutical Inc.5ASTRAZENECA2LEADING2BOEHRINGER INGELHEIMBoehringer Ingelheim CorpDana-Farber Cancer Institute IncJOHNSON & JOHNSON
drugs
osimertinib mesylate2RYBREVANTamivantamab
topics
Oncology25Pulmonology24NSCLC20EGFR13Rare Disease5Approval2DermatologySmall Molecule

related stories

  • 6d agoCullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancerFierce Biotech
  • Aug 7BlossomHill, Latigo outshine IPO expectations with oversubscribed debutsFierce Biotech
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Dec 22Fierce Biotech Fundraising Tracker '26: Sling reels in $123M; Circle gathers $92.5MFierce Biotech
  • 1d agoSionna says good-bye to 46% of staffers, including execBioSpace